洛铂联合紫杉醇治疗局部晚期宫颈癌的临床研究

目的 评价洛铂联合紫杉醇新辅助化疗方案在治疗局部晚期宫颈癌的疗效和不良反应.方法 从本院宫颈癌患者中选取宫颈癌Ⅰb2-Ⅱa期患者68例,分为实验组32例（洛铂联合紫杉醇）,对照组36例（紫杉醇联合顺铂）,观察洛铂联合紫杉醇新辅助化疗的疗效及不良反应.结果 实验组完全缓解（CR）4例,部分缓解（PR）24例,稳定（SD）4例,进展（PD）0例,总有效率87.5％;对照组CR2例,PR 28例,SD 6例,PD 0例,总有效率83.3％,2组疗效差异无统计学意义（P＞0.05）.实验组不良反应多为轻中度的骨髓抑制和消化道反应,对症治疗后恢复正常,肾毒性轻微,患者可耐受.结论 洛铂联合紫杉醇化疗方案治疗宫颈癌有较好疗效,不良反应可耐受,肾毒性少.

Clinical research of lobaplatin plus paclitaxel in treating locally advanced cervical cancer

Objective To evaluate the effect of neoadjuvant chemotherapy lobaplatin （LBP） plus paclitaxel in treatment of locally advanced cervical cancer and its adverse reaction. Methods 68 patients in the period Ib2 to II a from the cervical cancer patients were selected in our hospital, which was divided into two groups, namely the test group treated with LBP plus paclitaxel and the control group treated with paclitaxel plus cisplatin. Results Among the 32 patients in the test group,4 patients were complete remission （CR）, 24 patients were partial remission （PR） ,4 patients were steady （SD） and none had progressive disease （PD）. The total effective rate in the test group reached to 87.5% ,which was no significant difference compared with the control group. Meantime, the major adverse reactions in the test group included myelosuppression, nausea, vomiting, but all tolerated. Conclusion LBP plus paclitaxel isan effective therapy for cervical cancer, in which the adverse reaction is tolerated and the renal toxicity is slight.